EARLY diagnosis for Alzheimers.

Foresight Design.
RetinAid, an early diagnosis tool that detects Alzheimer’s decades before symptoms appear, using retinal biomarkers to enable early intervention and transform future care.

A Painting Tool.

An on-the-go art assistant that removes the learning curve of live painting, enabling anyone to create hyperrealistic works from day one — no lessons or practice needed.

2025

Fearful social stigma surrounding Diagnosis

3,500 active researchers working on dementia-related studies

NHS and private research institutes are segmented

NHS yet to provide funding for effective treatments

The NHS has over 55 million patient records

1 in 4 Hospital Beds are occupied by dementia patients

industry consultations

AD treatment advance to being able to stop progression and are approved by NICE and MHRA

1 billion+ expected for diagnosis funding

A centralised NHS database of population data

Technological improvements in drug application to brain

Reduced negative stigma surrounding dementia diagnosis

Community based healthcare implementation across UK

2055

lengthy diagnosis process projection in 2055

In 30 years, when early intervention directly correlates to the effectiveness of treatment,

How can we design an accurate and inclusive intervention for nationwide Alzheimer's diagnosis?

RetinAiD, a screening device for Alzheimer's Disease

RetinAiD conducts OCTA scans at regular intervals, tracking retinal changes over time to identify potential onset of Alzheimer’s, up to 10 years before clinical symptoms occur.

The core tech enabler, OCTA scanning, is a non-invasive method to access brain information.

3D images of the back of the retina are taken and analysed for changes in blood vessel patterns, which directly correlate with early-onset Alzheimer's.

Patient data tracked over time and directly integrated into the NHS system.

system experience

Nationwide NHS savings calculation from the benefit of RetinAiD